First patient dosed with AgenTus’ cell therapy designed to clear COVID-19 virus while reducing inflammation

First patient dosed with AgenTus’ cell therapy designed to clear COVID-19 virus while reducing inflammation

Source: 
Biopharma Reporter
snippet: 

Agenus Inc, an immuno-oncology company with a pipeline of agents designed to activate immune response to cancers and infectious diseases, has reported the dosing of the first COVID-19 patient with agenT-797, an allogeneic cell therapy, through its subsidiary, AgenTus Therapeutics.